Sanara MedTech Inc. (SMTI) Form 10-Q — Aug 11, 2026
Sanara MedTech's Q2 2026 10-Q discloses that on July 29, 2026 the company signed a definitive merger agreement under which MiMedx Group will acquire it, with each SMTI share converting into $33.00 in cash plus 0.4735 MiMedx shares. If completed, Sanara becomes a wholly owned MiMedx subsidiary and its stock will be delisted from Nasdaq. The deal requires Sanara shareholder approval, SEC effectiveness of the S-4 registration statement, and Hart-Scott-Rodino clearance; holders of approximately 38.9% of voting power have signed a voting agreement.
Key figures
- Revenue
- 28136757
- Total Debt
- 46477087
- Revenue Yoy
- 9.0% (Q2 YoY); 13.6% (six months YoY)
- Total Assets
- 69146387
- Cash Position
- 15421170
- Interest Rate
- 13.25
- Maturity Date
- March 30, 2029
- Shares Outstanding
- 9188035
- Adjusted Ebitda Q2
- 5010778
- Revenue Six Months
- 55935291
- Merger Cash Per Share
- 33
- Net Income Six Months
- 5739
- Bmi Ownership Percent
- 11.945%
- Crg Term Loan Facility
- up to $55.0 million senior secured (13.25% rate; 8.00% cash / 5.25% PIK-eligible)
- Termination Fee Parent
- 22540785
- Voting Agreement Stake
- 38.9% of voting power
- Termination Fee Company
- 9660336
- Bmi Total Cash Investment
- 9000000
- Thp Impairment Prior Year
- 26472407
- Adjusted Ebitda Six Months
- 9272946
- Estimated Fair Value Of Debt
- 56.6 million vs 46.5 million carrying amount
- Merger Stock Consideration
- 0.4735 MiMedx shares per SMTI share
- Revenue Six Months Prior Year
- 49238348
Price after filing
Close on the filing date to close N calendar days later (from $34.25). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.